The whole RSV vaccine field took a beating when the CDC’s immunization committee doled out a limited recommendation last ...

Hello everyone. Welcome to today's call and webcast. The presentation was sent to our distribution list by e-mail today, and you can also find it on gsk.com. Please turn to Slide 2. This is the usual ...

The research adds to growing recognition that infectious agents may play a role in the development of some types of dementia.

New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older ...

GSK Plc’s long-acting HIV prevention drug is as safe in pregnant women as daily pills, a boost to the company’s efforts to ...

In the study, Shingrix had a 17 per cent lower risk of dementia than Zostavax and a lower risk of between 23 and 27 per cent ...

In HIV treatment, Gilead Sciences’ popular Biktarvy serves as a benchmark for newer drugs to overcome. | In a new head-to-head study, GSK's two-drug regimen Dovato showed comparable antiviral efficacy ...

In GSK, the Federal Circuit affirmed a jury verdict that Teva’s labeling and marketing materials for its generic carvedilol product induced infringement of GSK’s patent claiming “[a] method ...

Good day and thank you for standing by. Welcome to the Moderna second quarter 2024 conference call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will ...

Glaxo (GSK) delivered earnings and revenue surprises of 9% and 4.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October ...

US stock markets have surged as investors bet that the US Federal Reserve will signal that lower interest rates are on the ...